3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Esophageal Squamous Cell Carcinoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Rectal Diseases
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
32
Cisplatin
31
durvalumab
15
pembrolizumab
14
Fluorouracil
13
Oxaliplatin
12
Leucovorin
12
Capecitabine
10
Bevacizumab
8
lenvatinib
7
Nivolumab
7
zanidatamab
4
Trastuzumab
4
S 1 (combination)
4
Paclitaxel
4
Liquid Biopsy
4
Irinotecan
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
tremelimumab
3
tislelizumab
3
irinotecan sucrosofate
3
Injections
3
Folfox protocol
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
niraparib
2
ivosidenib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Levoleucovorin
×
1 year
×
Clear all
NCT06428409
2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled